Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Healthcare

Amal advances to $365m acquisition
Boehringer Ingelheim will pay a total of up to $365m to acquire its venture fund's portfolio company Amal Therapeutics, an immunotherapy spinout of University of Geneva.
Orchestra BioMed composes $34m series B1
Orchestra BioMed has confirmed Temuro’s participation in a $34m series B1 round, a month after the corporate entered into a strategic agreement that had it invest $5m of equity.
Analysis: Biontech gets a $325m series B round
Cancer treatment company Biontech raised $325m round backed by Fidelity. The company forms part of the hopeful oncology and cancer treatment subsector of life sciences which has seen much growth and in corporate backing in recent years.
GNS galvanises corporates for $23m series D
The AI-powered drug discovery platform received commitments from Echo Health Ventures, Amgen Ventures, Alexandria Venture Investments and Celgene in the Cigna-led round.
Juventas stays young with Casi-backed series A-plus
Casi Pharmaceuticals took part in drug developer Juventas' $14.5m series A-plus round after licensing the latter's Car T-cell drug candidate for haematological malignancies last month.
Biontech completes $325m series B
Fidelity Management & Research has led a $325m series B round for Biontech, a spinout of Johannes Gutenberg University Mainz whose backers also include Sanofi and Pfizer.
IGM Biosciences amasses $102m series C
Haldor Topsøe has returned to participate in a $102m series C round for the cancer treatment developer.
Evotec reaches Breakpoint with $35m
Evotec has spun out Breakpoint Therapeutics and equipped the oncology drug developer with $35m in funding also backed by Taiho Pharmaceutical.

Other News

Belong.Life takes home $14m series B
Belong.Life, the operator of a cancer-focused online support network, will use the Iqvia-led round to expand its Belong Patient Engagement Platform.
Gradient returns to BenchSci
The machine learning-powered biological research startup has increased its overall funding to $20.8m following an investment from Google's Gradient Ventures unit.
Citryll completes first series A close
Autoimmune disease drug maker Citryll has hit the first close of a targeted $19m series A, having sourced commitments from BrightGene and ModiQuest.
Corporate venturing deal net: 1-5 July 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Synyi signs up Tencent for series C round
The China Electronics and Shulan Health-backed medical data processing software provider collected $36.3m in a Tencent-led round that included Sinopharm.
CureApp secures $20m funding
Itochu Technology Ventures, Dai-ichi Life, Mizuho Capital and Mori Trust have contributed to a $20m round that increased the medical access app developer’s total funding to nearly $39m.

Editor's Picks

BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
Pfizer’s Jones to retire
Elaine Jones, vice-president at pharmaceutical company Pfizer’s corporate venture capital unit, has shared highlights of her career with GCV ahead of her departure in April.
M&A of the Year: Prexton Therapeutics
Having emerged from the Merck Serono Entrepreneur Partnership Program (EPP) in 2015, Prexton Therapeutics raised a total $41m of funding before it was acquired by pharmaceutical firm Lundbeck for an estimated $1.1bn last year.
CVC in 2018 - The Trends: Part Two
In the second half of our guide to corporate venturing's biggest trends in 2018, we look at the growth of Chinese tech companies, genomics, advances in transport tech and the growth of the scooter rental space.
test reg

Login